Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Journal of Biomedical and Techno Nanomaterials
Adwoa Agyemang
Legon School of Business
Biochemistry, Genetics & Molecular Biology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
NUCLEIC ACID AND PROTEIN-BASED NANOTHERAPEUTICS FOR PRECISION MEDICINE Adwoa Agyemang; Samuel Bediako; Kwame Mensah
Journal of Biomedical and Techno Nanomaterials Vol. 3 No. 2 (2026)
Publisher : Yayasan Adra Karima Hubbi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70177/jbtn.v3i2.3961

Abstract

Nucleic acid and protein-based nanotherapeutics have emerged as revolutionary approaches in the field of precision medicine, offering highly targeted treatments for various diseases, including cancer, genetic disorders, and viral infections. Traditional therapies often face challenges such as off-target effects, limited bioavailability, and inadequate therapeutic outcomes. Nanotechnology, leveraging the unique properties of nucleic acids (DNA/RNA) and proteins encapsulated in nanomaterials, provides solutions to these limitations by enabling controlled drug release, targeted delivery, and enhanced therapeutic efficacy. This study explores the potential of nucleic acid and protein-based nanotherapeutics in precision medicine, focusing on their mechanisms, applications, and future prospects. The research employs in vitro and in vivo models to evaluate the delivery efficiency, biocompatibility, and therapeutic effectiveness of these nanotherapeutics. The results indicate that nucleic acid-based nanoparticles, such as siRNA and DNA, show significant efficacy in gene silencing and expression modulation, while protein-based nanocarriers demonstrate enhanced targeting of specific cells and tissues. In conclusion, nucleic acid and protein-based nanotherapeutics offer promising advances in precision medicine, providing a new paradigm for treating diseases with high specificity and reduced side effects.
Co-Authors Kwame Mensah Samuel Bediako